Fatigue is one of the most common and distressing side effects of cancer and its treatment, and may persist for years after treatment completion in otherwise healthy survivors. Guided by basic research on neuro-immune interactions, a growing body of research has examined the hypothesis that cancerrelated fatigue is driven by activation of the pro-inflammatory cytokine network. In this review, we examine the current state of the evidence linking inflammation and cancer-related fatigue, drawing from recent human research and from experimental animal models probing effects of cancer and cancer treatment on inflammation and fatigue. In addition, we consider two key questions that are currently driving research in this area: what are the neural mechanisms of fatigue, and what are the biological and psychological factors that influence the onset and/or persistence of inflammation and fatigue in cancer patients and survivors? Identification of the mechanisms driving cancer-related fatigue and associated risk factors will facilitate the development of targeted interventions for vulnerable patients.
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Introduction
Fatigue is increasingly recognized as one of the most common and distressing side effects of cancer and its treatment (Lawrence et al., 2004) . Prevalence estimates of fatigue during cancer treatment range from 25% to 99% depending on the sample, type of treatment, and method of assessment (Servaes et al., 2002; Lawrence et al., 2004) . Energy typically improves in the year after treatment completion, although a significant minority of patients continue to experience fatigue for months or years after successful treatment (Bower et al., 2000; Cella et al., 2001 ). Studies of longterm cancer survivors suggest that approximately one-quarter to one-third experience persistent fatigue for up to 10 years after cancer diagnosis (Bower et al., 2006; Servaes et al., 2006) . Fatigue has a negative impact on work, social relationships, mood, and daily activities and causes significant impairment in overall quality of life (Andrykowski et al., 1998; Bower et al., 2000; Broeckel et al., 1998) . Fatigue may also be a predictor of shorter survival in cancer patients (Groenvold et al., 2007) .
Qualitative reports suggest that cancer-related fatigue is more severe, more enduring, and more debilitating than ''normal'' fatigue caused by lack of sleep or overexertion and is not relieved by adequate sleep or rest (Poulson, 2001 ). In addition, cancer-related fatigue involves mental, physical, and emotional components. One definition that captures several of the key features of cancer-related fatigue describes it as ''a subjective state of overwhelming and sustained exhaustion and decreased capacity for physical and mental work that is not relieved by rest '' (Cella et al., 1998) .
Studies conducted over the past decade have begun to elucidate the biological underpinnings of cancer-related fatigue, with a focus on inflammation. This research is motivated by basic research on neural-immune signaling, which indicates that pro-inflammatory cytokines can signal the central nervous system to generate symptoms of fatigue and other behavioral changes in animals and healthy humans (Dantzer et al., 2008) . In the cancer context, inflammation may be induced by common cancer treatments, including radiation and chemotherapy, or by the tumor itself. Previous reviews of this literature have generally supported a link between inflammation and behavioral symptoms in cancer patients, including fatigue (Miller et al., 2008; Schubert et al., 2007; Seruga et al., 2008; Bower, 2007) . This is a growing area of research that has seen important advances in methodological rigor (e.g., larger sample sizes, controls for confounders, advanced statistical methods) and examination of underlying mechanisms. In this review we will examine the current state of the evidence linking inflammation and cancer-related fatigue, drawing from recent human research and from experimental animal models probing effects of cancer and cancer treatment on inflammation and fatigue. We will
